A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07619443
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MK-7262 — DRUG
    Oral administration
  • Enlicitide — DRUG
    Oral administration

Study Details

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Key Dates

Start date
Jul 6, 2026
Status verified
Jun 2026
Primary completion
Sep 5, 2026
Completion
Sep 12, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: MK-7262
    Participants will receive MK-7262 orally.
  • Experimental: Enlicitide
    Participants will receive enlicitide orally.
  • Experimental: MK-7262 plus Enlicitide
    Participants will receive MK-7262 and enlicitide orally.

Primary Outcome Measure

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262 [ Time Frame: Predose and at designated time points post-dose (up to 8 days) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion ( Site 0001)LincolnNebraska68502
Study Coordinator
402-476-2811

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies